FindTrial
Sign In

Evaluation of effects of transcranial magnetic stimulation in Parkinsons disease patients with freezing of gait

Evaluation of effects of repetitive trans cranial magnetic stimulation (rTMS) at supplementary motor area (SMA)in Parkinson�s disease (PD) patients with freezing of gait (FOG) : A Randomized Sham Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025515
Enrollment
30
Registered
2020-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

Intervention1: Real repetitive transcranial magnetic stimulation (rTMS) at 5 Hz & 10 Hz: Group 1: 5 sessions of real rTMS 5000 pulses at 5 Hz, Group 2: 5 sessions of real rTMS 5000 pulses at 10 Hz,

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Idiopathic PD patients aged 50-80years of age presenting with FOG 2. Modified Hoehn & Yahr scale 1.5-3 3. On Stable dopaminergic medicine for past 3 months 4. The mini-mental state examination (MMSE) questionnaire score > 24 points 5. Informed written consent

Exclusion criteria

Exclusion criteria: 1. History of brain tumour, stroke, traumatic brain injury, epilepsy or seizure in lifetime 2. History of major depression, psychosis, dementia (MMSE�24) 3. Implanted pacemaker, intra-cardiac lines, pumps or stimulators, or metallic foreign bodies inside the eye or skull (Dental fillings and braces are allowed) 4. Pregnancy (negative UPT in 2 weeks) 5. History of exposure to rTMS in the past

Design outcomes

Primary

MeasureTime frame
Change in the FOG Q score pre treatment (T0) & post treatment between two groups (T1, T2 & T3)Timepoint: T0 baseline T1after 5th session of sham rTMS T2 after 5th session of real rTMS T3 after 4 weeks—

Secondary

MeasureTime frame
Change in UPDRS motor score, LED &PDQ 39 pretreatment (T0) & post treatment between two groups (T1, T2 & T3)Timepoint: T0 baseline T1after 5th session of sham rTMS T2 after 5th session of real rTMS T3 after 4 weeks—

Countries

India

Contacts

Public ContactDr Divya M R

AIIMS New Delhi

dr.divyamr@gmail.com9958034273

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026